ENXTPA:SANPharmaceuticals
How Tolebrutinib’s MS Setback and China Wins Will Impact Sanofi (ENXTPA:SAN) Investors
Sanofi recently reported that its PERSEUS Phase 3 trial found the multiple sclerosis drug tolebrutinib failed to delay disability progression in primary progressive MS, leading the company to stop seeking approval for this indication while the FDA review for non‑relapsing secondary progressive MS is pushed beyond the previously expected December 2025 decision date.
At the same time, Sanofi has expanded its presence in rare blood disorders in China with approvals for Qfitlia in hemophilia and...